Professional Documents
Culture Documents
Povidone-Iodine/Dexamethasone Ophthalmic
Suspension for Treatment of Adenoviral
Conjunctivitis
JAY S. PEPOSE, ARJUN AHUJA, WENLEI LIU, ABHIJIT NARVEKAR, AND REZA HAQUE
PURPOSE: To evaluate the efficacy/safety of an Published by Elsevier Inc. This is an open access article
ophthalmic suspension of povidone-iodine (PVP-I) under the CC BY-NC-ND license (http://
0.6% and dexamethasone 0.1% in patients with acute creativecommons.org/licenses/by-nc-nd/4.0/).)
adenoviral conjunctivitis.
DESIGN: Multicenter, randomized, vehicle-controlled,
A
double-masked trial. CUTE CONJUNCTIVITIS IS A COMMON CONDITION,
METHODS: Adults with a positive Rapid Pathogen estimated to affect approximately 6 million people
Screening Adeno-Detector Plus test were randomized each year in the United States.1 Viruses and bacte-
1:1:1 to PVP-I 0.6%/dexamethasone 0.1%, PVP-I ria are the most common pathogens associated with acute
0.6%, or vehicle, bilaterally 4 times daily for 5 days infectious conjunctivitis, with adenoviruses considered to
(days 1-5). Patients were evaluated on days 3, 6, and 12 be the most frequent cause of viral conjunctivitis.2 Adeno-
(D1-day window). Efficacy measures included clinical viral conjunctivitis can cause significant discomfort and
resolution and adenoviral eradication. lost productivity. Although mostly self-limiting, in some
RESULTS: Overall, 144 patients were included in the cases it can lead to complications from long-term
efficacy analysis (PVP-I/dexamethasone, n [ 48; PVP- immune-mediated sequelae.3 Adenoviruses are nonenvel-
I, n [ 50; vehicle, n [ 46). The proportion of patients oped viruses that are relatively resistant to disinfection,4
with clinical resolution (primary study eye with last and adenoviral conjunctivitis is more contagious than
observation carried forward [LOCF]) at the day 6 visit other forms of conjunctivitis owing in part to adenoviruses
was higher with PVP-I/dexamethasone (31.3%) than being able to survive in a desiccated state for several weeks
with vehicle (10.9%; P [ .0158) and PVP-I (18.0%; at room temperature.5
P [ nonsignificant). The proportion with adenoviral No medications are currently approved for the treatment
eradication (primary study eye with LOCF) was higher of adenoviral conjunctivitis, and treatment is mostly
with PVP-I/dexamethasone than with vehicle at the day supportive. A novel topical ophthalmic suspension of
3 (35.4% vs 8.7%; P [ .0019) and day 6 (79.2% vs povidone-iodine (PVP-I) 0.6% and dexamethasone 0.1%
56.5%; P [ .0186) visits and vs PVP-I (day 3 visit, is under clinical investigation, and has the potential to treat
32.0%; day 6 visit, 62.0%; each P [ nonsignificant). both the viral and inflammatory components of adenoviral
Treatment-emergent adverse events (AEs) occurred in conjunctivitis as well as immune-related sequelae such as
69.0% (vehicle), 62.7% (PVP-I), and 53.4% (PVP-I/ subepithelial infiltrates. Dexamethasone is a potent, well-
dexamethasone) of patients in the safety dataset. Discon- tolerated corticosteroid6,7 routinely used as a topical
tinuation owing to AEs occurred in 37 patients (vehicle, ophthalmic antiinflammatory agent.8,9 PVP-I is an anti-
n [ 16; PVP-I, n [ 12; PVP-I/dexamethasone, n [ 9). septic used in ophthalmology and general surgery.10–12
CONCLUSION: PVP-I/dexamethasone appeared safe The combination of PVP-I and dexamethasone in
and well tolerated, and significantly improved clinical various formulations has been studied in several preclinical
resolution and adenoviral eradication in patients with and early-stage clinical trials. These include a study using a
acute adenoviral conjunctivitis. (Am J Ophthalmol rabbit model of adenoviral keratoconjunctivitis, in which
2018;194:7–15. Ó 2018 Shire, Lexington, MA, USA. treatment with PVP-I 0.4%/dexamethasone 0.1% resulted
in significantly improved clinical scores and significantly
Accepted for publication May 10, 2018. reduced viral titers compared with control treatments.13
From Pepose Vision Institute, Chesterfield, Missouri, USA (J.S.P.); In an open-label trial of 6 patients with acute conjunctivitis
Department of Ophthalmology and Visual Sciences, Washington
University School of Medicine, St. Louis, Missouri, USA (J.S.P.); Seth who were positive for adenovirus by the Rapid Pathogen
Gordhandas Sunderdas Medical College and King Edward Memorial Screening Adeno-Detector test, clinical resolution and
Hospital, Mumbai, India (A.A.); and Shire, Lexington, Massachusetts, reduction of viral titer occurred within 5 days of treatment
USA (W.L., A.N., R.H.).
Inquiries to Reza Haque, Shire, 300 Shire Way, Lexington, MA 02421, with PVP-I 0.4%/dexamethasone 0.1% 4 times daily
USA; e-mail: rhaque@shire.com (QID).14 In a randomized controlled trial of 122 patients
Discontinued the study (n=13) Discontinued the study (n=15) Discontinued the study (n=24)
• Adverse events (n=9) • Adverse events (n=12) • Adverse events (n=16)
• Subject’s decision (n=2) • Subject’s decision (n=2) • Lack of efficacy (n=2)
• Administrative reasons • Administrative reasons • Subject’s decision (n=6)
(n=2) (n=1)
FIGURE 2. Patient disposition. aOne patient was randomized but did not receive study treatment; this patient discontinued at visit 1
(subject decision) and was excluded from all analysis populations. ITT [ intent-to-treat; PVP-I [ povidone-iodine.
Age, mean (SD), years 33.7 (12.3) 35.1 (11.0) 34.6 (13.3) 34.5 (12.2)
Sex, n (%)
Male 39 (67.2) 40 (67.8) 37 (63.8) 116 (66.3)
Female 19 (32.8) 19 (32.2) 21 (36.2) 59 (33.7)
Race, n (%)
Asian 58 (100) 59 (100) 58 (100) 175 (100)
PVP-I ¼ povidone-iodine.
measured by assessment of drop comfort at the day 1 visit by population, a subset of the ITT population (randomized pa-
the patient upon instillation (administered by a designated tients who received >_1 dose of study medication) who had
staff member), and at 1 and 2 minutes after instillation using positive CC-IFA results in > _1 eye at day 1, watery conjunc-
a 0-10 scale (0 ¼ very comfortable, 10 ¼ very uncomfortable). tival discharge and bulbar conjunctival redness scores > _1 in
IOP was not measured during the study. the same eye at day 1, and > _1 follow-up visit. All analyses
except crossover infection were conducted using the pri-
STATISTICAL ANALYSES:The efficacy analysis was mary study eye, defined as the eye with a positive CC-
conducted on the modified intent-to-treat (mITT) IFA at day 1 or, if both/neither were infected, the eye
P=.0056
60 P=.0266
54.2
Patients, %
40 P=.0202
P=.0158
32.0 33.3
31.3
26.1
20
18.0 18.0
13.0
10.9
0
Clinical Resolution Watery Conjunctival Bulbar Conjunctival
Discharge Score=0 Redness Score=0
FIGURE 3. Clinical resolution, watery conjunctival discharge, and bulbar conjunctival redness at day 6 (D1-day window; modified
intent-to-treat population with last observation carried forward, primary study eye). Clinical resolution was defined as the absence
(score [ 0) of both watery conjunctival discharge and bulbar conjunctival redness. Watery conjunctival discharge and bulbar
conjunctival redness were scored on a scale of 0 (absent/normal) to 3 (severe). Only statistically significant P values (< .05) are
shown; all other comparisons between treatment groups were nonsignificant. PVP-I [ povidone-iodine.
with the highest global clinical score. If both eyes had the (Figure 2). The safety and ITT populations included 175
same score, the right eye was the study eye. Analysis of the patients. The mITT population included 144 patients.
crossover infection data was conducted using the clinically The mean (standard deviation) age across all patients in
worse study eye definition (eye with the highest global clin- the ITT population was 34.5 (12.2) years. Two thirds of pa-
ical score at baseline or, if both eyes had the same global tients were male (66.3%) and all were Asian (Table 1).
clinical score at baseline, the right eye). The nonstudy Three patients in the vehicle group and 1 patient in the
eye was designated as the fellow eye. PVP-I/dexamethasone group were recorded as noncompli-
Binary efficacy endpoints were compared between treat- ant with dosing.
ment arms using Pearson x2 or Fisher exact tests (in the case Serotype data were available for 18 patients (6 in the
of expected counts < 5); change from baseline in global clin- PVP-I/dexamethasone group, 5 in the PVP-I group, and 7
ical score and raw score were compared between treatment in the vehicle group), most of whom had serotype data
arms using the 2-sample t test, at the 2-sided .05 significance across multiple visits. Of these, 17 patients had the D8
level with missing data imputed by last observation carried for- serotype in both eyes. At visits 1 and 2, 1 patient in the
ward (LOCF). Formal sample size calculations were not vehicle arm had the B3 serotype in the fellow eye and
performed, as this trial was a proof-of-concept study. However, the D8 serotype in the study eye.
a sample size of 160 evaluable patients (approximately 53-54
per treatment arm) was deemed reasonable to assess safety CLINICAL RESOLUTION: After 5 days of treatment (day 6
and provide information for powering future studies. visit), the proportion of patients with clinical resolution in
the primary study eye was significantly higher in the PVP-
I/dexamethasone group (31.3% [15/48]) compared with the
vehicle group (10.9% [5/46], P ¼ .0158), and numerically
RESULTS higher compared with the PVP-I group (18.0% [9/50], P ¼
nonsignificant [NS]) (Figure 3). At the day 6 visit, a greater
STUDY POPULATION: The study was conducted between proportion of patients also had complete resolution of the in-
December 17, 2012 and May 23, 2014. A total of 176 pa- dividual signs with PVP-I/dexamethasone compared with
tients were randomized, and 124 completed the study vehicle (P ¼ .0056 for discharge, P ¼ .0202 for redness) or
60
Patients, %
62.0
56.5
P=.0019
40 P=.0050
35.4
32.0
20
8.7
0
Day 3+1 Day 6+1 Day 12+1
(Visit 2) (Visit 3) (Visit 4)
FIGURE 4. Adenoviral eradication at days 3, 6, and 12 (D1-day window; modified intent-to-treat population with last observation
carried forward, primary study eye). Adenoviral eradication was defined as a negative cell culture immunofluorescence assay result.
Only statistically significant P values (< .05) are shown; all other comparisons between treatment groups were nonsignificant.
PVP-I [ povidone-iodine.
PVP-I (P ¼ .0266 for discharge, P ¼ NS for redness). No pa- P ¼ .0009; day 12 visit, 95.8% [46/48] vs 71.7% [33/46],
tients had clinical resolution at the day 3 visit. By the day 12 P ¼ .0014), and compared with PVP-I at the day 6 visit
visit, 62.5% of patients (30/48) treated with PVP-I/ (77.1% [37/48] vs 52.0% [26/50], P ¼ .0096). The proportion
dexamethasone, 62.0% (31/50) treated with PVP-I, and of patients with expanded clinical cure was also numerically
45.7% (21/46) treated with vehicle had clinical resolution greater following treatment with PVP-I/dexamethasone
(P ¼ NS between treatment groups). than with PVP-I at the day 3 visit (35.4% [17/48] vs 18.0%
[9/50], P ¼ NS) and day 12 visit (95.8% [46/48] vs 84.0%
ADENOVIRAL ERADICATION: After 5 days of treatment [42/50], P ¼ NS). The proportion of patients with expanded
(day 6 visit), the proportion of patients with adenoviral clinical cure in the PVP-I group was not significantly
eradication in the primary study eye was significantly different from that in the vehicle group at all visits.
greater following treatment with PVP-I/dexamethasone
(79.2% [38/48]) compared with vehicle (56.5% [26/46], GLOBAL CLINICAL SCORE: Reductions from baseline in
P ¼ .0186), and numerically greater compared with PVP- the global clinical score were significantly greater following
I (62.0% [31/50], P ¼ NS) (Figure 4). Adenoviral eradica- treatment with PVP-I/dexamethasone compared with
tion with PVP-I/dexamethasone was evident as early as at vehicle at all visits (mean change from baseline: day 3 visit,
the day 3 visit, and remained statistically significantly –1.7 vs –0.9, P ¼ .0097; day 6 visit, –3.6 vs –2.1, P ¼ .0002;
greater compared with vehicle at the day 12 visit. day 12 visit, –4.3 vs –3.5, P ¼ .0468), and at the day 3 and day
The proportion of patients at the day 6 visit with both 6 visits compared with PVP-I (day 3 visit, –1.7 vs –1.1,
adenoviral eradication and clinical resolution was signifi- P ¼ .0370; day 6 visit, –3.6 vs –2.6, P ¼ .0057; day 12 visit,
cantly greater in the PVP-I/dexamethasone group (31.3% –4.3 vs –4.1, P ¼ NS). The proportion of patients in the
[15/48]) than in the vehicle group (6.5% [3/46]; PVP-I/dexamethasone group with any improvement from
P ¼ .0023), and numerically greater than in the PVP-I baseline in global clinical score was significantly greater
group (18.0% [9/50], P ¼ NS) (Figure 5). than with vehicle at all visits (day 3 visit, 81.3% vs 56.5%,
P ¼ .0095; day 6 visit, 97.9% vs 76.1%, P ¼ .0015; day 12
EXPANDED CLINICAL CURE: The proportion of patients visit, 100% vs 87.0%, P ¼ .0115), and significantly greater
achieving expanded clinical cure with PVP-I/ than PVP-I at the day 3 (81.3% vs 60.0%, P ¼ .0212) and
dexamethasone was significantly greater compared with day 6 (97.9% vs 82.0%, P ¼ .0158) visits.
vehicle at all visits (day 3 visit, 35.4% [17/48] vs 8.7% [4/ At all visits, compared with vehicle, a significantly greater
46], P ¼ .0019; day 6 visit, 77.1% [37/48] vs 43.5% [20/46], proportion of patients in the PVP-I/dexamethasone group
60
60.4
58.0
Patients, %
40 P=.0023 41.3
31.3
20
18.0
6.5
0
Day 3+1 Day 6+1 Day 12+1
(Visit 2) (Visit 3) (Visit 4)
FIGURE 5. Both adenoviral eradication and clinical resolution at days 3, 6, and 12 (D1-day window; modified intent-to-treat pop-
ulation with last observation carried forward, primary study eye). Adenoviral eradication was defined as a negative cell culture immu-
nofluorescence assay result. Clinical resolution was defined as the absence (score [ 0) of both watery conjunctival discharge and
bulbar conjunctival redness. Only statistically significant P values (< .05) are shown; all other comparisons between treatment
groups were nonsignificant. PVP-I [ povidone-iodine.
PVP-I ¼ povidone-iodine.
ocular TEAEs were corneal infiltrates, punctate keratitis, reduction from baseline of >_2 points (out of a maximum to-
eyelid edema, and conjunctivitis. Most events occurred tal score of 6) in the global clinical score compared with
more frequently in the PVP-I and vehicle groups than in 39.1% in the vehicle group. A smaller proportion
the PVP-I/dexamethasone group (Table 3). (35.4%) of patients treated with PVP-I/dexamethasone
There were no safety concerns raised in any of the clin- demonstrated adenoviral eradication at the day 3 visit,
ical examinations (including BCVA and slit-lamp bio- suggesting that patients receiving this treatment should
microscopy). Mean drop comfort scores upon instillation be counseled to continue to take precautions for > _6 days
were similar among all treatment groups and were 2 or 3 to prevent spread of the infection. Overall, these results
on a scale from 0 (very comfortable) to 10 (very uncomfort- suggest that PVP-I/dexamethasone may be effective at
able). quickly eradicating the virus and improving clinical signs,
which could benefit quality of life and minimize the spread
of infection. A rapid improvement of conjunctivitis is also
expected to have a positive socioeconomic impact because
DISCUSSION patients are able to return to school or work sooner.
PVP-I/dexamethasone appeared to be safe and well
THE RESULTS OF THIS STUDY INDICATE THAT AN tolerated in this study, with a lower proportion of patients
ophthalmic suspension of PVP-I 0.6% and dexamethasone in the PVP-I/dexamethasone group (53.4%) experiencing
0.1% is safe and well tolerated for the treatment of acute TEAEs than in the vehicle (69%) or PVP-I (62.7%)
adenoviral conjunctivitis. Outcomes for PVP-I 0.6%/dexa- groups. There were no serious AEs during the study, no
methasone 0.1% showed statistical superiority compared TEAEs were suspected of being related to study treatment,
with vehicle for clinical resolution, adenoviral eradication, and the majority of TEAEs in each treatment group were
expanded clinical cure, and multiple parameters of global mild in severity. In addition, the drop tolerability of
clinical score. Trends to improvement relative to PVP-I PVP-I 0.6%/dexamethasone 0.1% was acceptable, with
alone were also observed. The outcomes for the PVP-I drop comfort scores similar to those in the vehicle group.
group did not show statistical superiority to vehicle, with This is noteworthy because drop comfort is a component
the exception of adenoviral eradication at the day 3 visit. of ocular tolerability, and ocular discomfort can influence
Adenoviral conjunctivitis typically lasts 14-21 days.17 In patient preference and treatment compliance.18
our study, the number of patients with complete adenoviral A study that used the adenovirus type 5/New Zealand
eradication was significantly higher in the PVP-I/ rabbit ocular model showed that corticosteroids alone can
dexamethasone group than in the vehicle group as early increase viral replication and the duration of viral shed-
as the day 3 visit, while the number of patients with both ding.19 However, results from the present study and
adenoviral eradication and clinical resolution was signifi- others14–16 suggest that PVP-I/dexamethasone does not in-
cantly higher in the PVP-I/dexamethasone group than in crease or prolong viral shedding, with adenoviral eradica-
the vehicle group at the day 6 visit. No patients achieved tion observed from day 3 through day 12 in our study. In
clinical resolution at the day 3 visit, but at this time point, addition, rapid adenoviral eradication and clinical resolu-
70.8% of patients in the PVP-I/dexamethasone group had a tion with PVP-I/dexamethasone should ensure that the
FUNDING/SUPPORT: THIS STUDY WAS FUNDED BY SHIRE, LEXINGTON, MASSACHUSETTS, USA. THE SPONSOR PARTICIPATED IN
the design of the study and in the collection, analysis, and interpretation of the data. Financial Disclosures: Jay S. Pepose has been a consultant for Foresight
Biotherapeutics, Okogen, and Shire. Wenlei Liu, Abhijit Narvekar, and Reza Haque are employees of and own stock and stock options in Shire Plc. The
following author has no financial disclosures: Arjun Ahuja. All authors attest that they meet the current ICMJE criteria for authorship.
Other Acknowledgments: The authors thank Nasser Malik, PhD, of Excel Medical Affairs, who provided medical writing assistance funded by Shire.